Friday, May 12, 2023
Our goal is to educate on the treatment of multiple myeloma, especially with respect to treatment options and, in particular, treatment in elderly fit and/or frail populations. Other patient populations include the indolent/biochemical relapsed patients and patients who have already been exposed to lenalidomide or daratumumab in prior lines of treatment.
Following attendance of this symposium, participants should be able to:
- Describe the need for communicating real-world clinical expertise in managing MM in older and/or frail patients who are not adequately represented in clinical trials – Philippe Moreau
- Identify factors that should be considered when selecting a treatment for older and/or frail patients with MM – Hira Mian
- State when frailty should be measured – Hira Mian
- Recall data for emerging therapies for RRMM – Paul Richardson